Viking Therapeutics Loses 20% in a Month: How to Play the Stock

Viking Therapeutics (VKTX) shares declined over 20% in the past month, underperforming benchmarks, following mixed mid-stage trial results for its oral obesity drug VK2735, which achieved efficacy but saw significant patient dropouts due to tolerability issues. This raises concerns about the drug's safety profile and intensifies competitive pressures from Eli Lilly and Novo Nordisk in the lucrative obesity market, compounded by Viking's lack of revenue, cash burn, and premium valuation, leading to a 'Sell' rating.

Analysis

Viking Therapeutics (VKTX) has experienced a significant valuation pullback, with shares declining over 20% in the past month and trading below the 50 and 200-day moving averages. The primary catalyst for this underperformance was the release of mixed top-line results from a mid-stage study of its oral obesity drug, VK2735. While the drug met its primary efficacy endpoints, demonstrating up to 12.2% weight loss, a significant patient dropout rate has introduced material concerns regarding its tolerability and safety profile. This development elevates the competitive risk posed by established pharmaceutical giants Eli Lilly and Novo Nordisk, who are advancing their own oral obesity candidates and are better capitalized to dominate the projected $100 billion market. Viking's fundamental position is further weakened by its lack of a revenue stream and ongoing cash burn, which is a considerable risk despite a stated cash position of $808 million and zero debt. The company's premium valuation, with a price-to-book ratio of 3.82 versus the industry's 3.09, appears increasingly difficult to justify, especially as analyst estimates for 2025 and 2026 losses have widened significantly. While the subcutaneous formulation of VK2735 remains in late-stage development, key updates are not anticipated until late 2026, leaving a prolonged period of uncertainty.

Key Decisions for Investors

• Given the stock's negative technical momentum and widening loss estimates, investors should re-evaluate their positions, as the mixed trial data on oral VK2735 introduces significant safety and commercial viability concerns.
• Closely monitor the regulatory progress of competitors Eli Lilly and Novo Nordisk, whose advancements in oral obesity drugs represent a direct and substantial threat to Viking's potential market share.
• For long-term holders, the investment thesis now hinges more heavily on the subcutaneous version of VK2735, acknowledging that key clinical updates are not expected until late 2026 and the company remains pre-revenue with significant cash burn.